title: Association between symptom improvement and change of body mass index, lipid profile, and leptin, ghrelin, and cholecystokinin levels during 6-week olanzapine treatment in patients with first-episode psychosis.
authors.forename: Cengiz
authors.initials: C
authors.lastname: Basoglu
authors.forename: Ozgur
authors.initials: O
authors.lastname: Oner
authors.forename: Alpay M
authors.initials: AM
authors.lastname: Ates
authors.forename: Ayhan
authors.initials: A
authors.lastname: Algul
authors.forename: Umit Basar
authors.initials: UB
authors.lastname: Semiz
authors.forename: Servet
authors.initials: S
authors.lastname: Ebrinc
authors.forename: Mesut
authors.initials: M
authors.lastname: Cetin
authors.forename: Omer
authors.initials: O
authors.lastname: Ozcan
authors.forename: Osman Metin
authors.initials: OM
authors.lastname: Ipcioglu
mesh_terms: D001569:Benzodiazepines / Q000008:administration & dosage*; D015992:Body Mass Index; D002766:Cholecystokinin / Q000097:blood*; D054439:Ghrelin / Q000097:blood*; D006801:Humans; D020738:Leptin / Q000097:blood*; D008055:Lipids / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000097:blood* / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D054439:Ghrelin; D020738:Leptin; D008055:Lipids; D008077:Lipoproteins, LDL; D014280:Triglycerides; D001569:Benzodiazepines; D002766:Cholecystokinin; D000077152:Olanzapine